Toggle Health Problems and D

Multiple Sclerosis is again not fought by 5,000 IU vitamin D daily (need at least 10X more) – RCT May 2023

  • Fighting MS with Vitamin D needs some combination of:
  • Larger Vitamin D doses: >50,000 IU if taken daily
  • Gut-friendly form of vitamin D
  • Magnesium - increases effective IU by 30%
  • Take Vitamin D with evening meal - increases effective IU by 30%
  • Vitamin D Receptor activators: i.e. Resveratrol, Curcumin
  • Take Vitamin D non-daily - say weekly - gets past any Vitamin D Receptor limitation

High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial

EClinicalMedicine. 2023 Apr 13;59:101957. doi: 10.1016/j.eclinm.2023.101957
Sandra D Cassard 1, Kathryn C Fitzgerald 1, Peiqing Qian 2, Susan A Emrich 1, Christina J Azevedo 3, Andrew D Goodman 4, Elizabeth A Sugar 5, Daniel Pelletier 3, Emmanuelle Waubant 6, Ellen M Mowry 1

About 1/2 year for the Vitamin D response to plateau

Background: Vitamin D insufficiency is associated with risk of multiple sclerosis (MS) relapse; whether supplementation influences prognosis is unknown. The Vitamin D to Ameliorate MS (VIDAMS) trial aimed to determine if high dose (5000 International Units (IU)/day) versus low dose (600 IU/day) vitamin D3, added to daily glatiramer acetate (GA), reduced the risk of clinical relapse in people with established relapsing-remitting MS (RRMS) over 96 weeks.

Methods: VIDAMS is a randomised, phase 3, double-blind, multi-centre, controlled trial conducted at sixteen neurology clinics in the United States. Participants with MAGNIMS 2010 RRMS, aged 18-50 years, with recent disease activity were eligible to enroll if they had an Expanded Disability Status Scale score ≤4.0; minimum serum 25-hydroxyvitamin D level of 15 ng/ml within 30 days of screening; and average ≤ 1000 IU supplemental vitamin D3 daily in the 90 days prior to screening. Of 203 screened, 183 were eligible for the 30-day run-in to assess GA adherence, after which 172 were randomised 1:1 to low dose vitamin D3 (LDVD) or high dose vitamin D3 (HDVD), and were followed every 12 weeks for 96 weeks. The primary outcome was the proportion that experienced a confirmed relapse and analyses used Kaplan Meier and Cox proportional hazards models. 165 participants returned for ≥1 follow-up visit and were included in the primary and safety analyses; 140 completed a week 96 visit. This study was registered with ClinicalTrials.gov, NCT01490502.

Findings: Between March 22, 2012 and March 8, 2019, 172 participants were enrolled and randomised (83 LDVD, 89 HDVD) and differed at baseline only in gender and race: more males received HDVD (31%) than LDVD (16%), and fewer Black participants received HDVD (12%) than LDVD (22%). Among 165 participants with at least one follow-up visit, the proportion experiencing confirmed relapse did not differ between LDVD and HDVD [at 96 weeks: 32% vs. 34%, p = 0.60; hazard ratio (HR): 1.17 (0.67, 2.05), p = 0.57]. There was no hypercalcaemia. Three participants developed nephrolithiasis or ureterolithiasis (1 in the LDVD and 2 in the HDVD group). Two were possibly related to study drug; and one was presumed related to concomitant treatment with topiramate for migraine.

Interpretation: VIDAMS provides evidence that HDVD supplementation, added to GA, does not reduce the risk of clinical relapse in people with RRMS. Taken together with the null findings of previous trials, these results suggest that prescribing higher doses of vitamin D for purposes of modifying the RRMS course may not be beneficial.

Funding: This investigation was supported by a grant from the National Multiple Sclerosis Society (RG 4407A2/1). Teva Neuroscience, Inc. provided Copaxone (GA) for the duration of the trial.
 Download the PDF from VitaminDWiki

VitaminDWiki - 11 studies in both categories Multiple Sclerosis and VitaminD Receptor

This list is automatically updated

VitaminDWiki - 2 studies in both categories Multiple Sclerosis and Magnesium

This list is automatically updated

VitaminDWiki – Overview MS and vitamin D contains

Clinical interventions have shown that Vitamin D can prevent, treat, and even cure Multiple Sclerosis, at a tiny fraction of the cost of the drugs now used to treat it, and without side effects.

Summary: lack of consensus on how much to prevent, treat, or cure MS.

VitaminDwiki – Better than Daily contains
25 items in BETTER THAN DAILY category

Non-daily (Bolus) is better:

  1. Better compliance for everyone
    • Fewer opportunities to forget.
    • If happen to forget, just take the pill days or weeks later
    • Fewer times to have to take a pill - for those who dislike doing so
  2. Non-daily is better the ~20% who have a poor Vitamin D Receptor
    • A high concentration gradient is one of 14 ways to get past Vitamin D Receptor limitations
    • So, while 80% get no extra benefit from non-daily dosing, 20% will get an extra benefit

40-150 ng of Vitamin D is needed to treat many health problems

Vitamin D Treats
150 ng Multiple Sclerosis *
80 ng Cluster Headache *
Reduced office visits by 4X *
70 ngSleep *
60 ngBreast Cancer death reduced 60%
Preeclampsia RCT
50 ng COVID-19
Infections Review
Infection after surgery
40 ng Breast Cancer 65% lower risk
ACL recovery
30 ng Rickets

* Evolution of experiments with patients, often also need co-factors

Attached files

ID Name Comment Uploaded Size Downloads
19529 5000 MS.jpg admin 01 May, 2023 12:55 59.07 Kb 71
19528 MS Vit D RCT_CompressPdf.pdf PDF 2023 admin 01 May, 2023 12:55 1.54 Mb 37